Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
Matthew J. Rees(Mayo Clinic), Shaji Kumar(Mayo Clinic), Arwa Bohra(Mayo Clinic in Arizona), David Dingli, Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Amit Khot(The Royal Melbourne Hospital), Saurabh Chhabra(Medical College of Wisconsin), Prashant Kapoor, Sikander Ailawadhi(Jacksonville College), Ricardo Parrondo(Jacksonville College), Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Eli Muchtar(Mayo Clinic), Radhika Bansal(Mayo Clinic in Arizona), Aytaj Mammadzadeh(Mayo Clinic in Arizona), Yi Lin, Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Mohammed Elhaj(Mayo Clinic in Arizona), Abiola Bolarinwa(Mayo Clinic in Arizona)
Cited by 20
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k